The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $3.85 in the prior trading day, Caribou Biosciences Inc (NASDAQ: CRBU) closed at $3.99, up 3.64%. In other words, the price has increased by $3.64 from its previous closing price. On the day, 1.38 million shares were traded. CRBU stock price reached its highest trading level at $4.07 during the session, while it also had its lowest trading level at $3.8.
Ratios:
Our goal is to gain a better understanding of CRBU by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.97 and its Current Ratio is at 11.97. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 31, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $13.
On July 11, 2023, Truist started tracking the stock assigning a Buy rating and target price of $23.Truist initiated its Buy rating on July 11, 2023, with a $23 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRBU now has a Market Capitalization of 360354848 and an Enterprise Value of 58635860. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.45 while its Price-to-Book (P/B) ratio in mrq is 0.96. Its current Enterprise Value per Revenue stands at 1.701 whereas that against EBITDA is -0.521.
Stock Price History:
The Beta on a monthly basis for CRBU is 2.54, which has changed by -0.07209301 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, CRBU has reached a high of $8.59, while it has fallen to a 52-week low of $3.44. The 50-Day Moving Average of the stock is -31.86%, while the 200-Day Moving Average is calculated to be -29.71%.
Shares Statistics:
The stock has traded on average 1.60M shares per day over the past 3-months and 1592410 shares per day over the last 10 days, according to various share statistics. A total of 88.45M shares are outstanding, with a floating share count of 79.62M. Insiders hold about 11.85% of the company’s shares, while institutions hold 78.15% stake in the company. Shares short for CRBU as of 1711584000 were 10201716 with a Short Ratio of 6.37, compared to 1709164800 on 9389085. Therefore, it implies a Short% of Shares Outstanding of 10201716 and a Short% of Float of 11.84.
Earnings Estimates
A comprehensive evaluation of Caribou Biosciences Inc (CRBU) is underway, with the input of 6 analysts contributing to its current rating.On average, analysts expect EPS of $-0.41 for the current quarter, with a high estimate of $-0.35 and a low estimate of $-0.49, while EPS last year was $-0.46. The consensus estimate for the next quarter is $-0.43, with high estimates of $-0.4 and low estimates of $-0.51.
Analysts are recommending an EPS of between $-1.6 and $-2.09 for the fiscal current year, implying an average EPS of $-1.79. EPS for the following year is $-2.08, with 7 analysts recommending between $-1.43 and $-2.97.
Revenue Estimates
5 analysts predict $2.9M in revenue for the current quarter. It ranges from a high estimate of $5M to a low estimate of $–. As of the current estimate, Caribou Biosciences Inc’s year-ago sales were $3.5M, an estimated decrease of -17.20% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $2.98M, a decrease of -20.60% less than the figure of $-17.20% in the same quarter last year. There is a high estimate of $5M for the next quarter, whereas the lowest estimate is $–.
A total of 7 analysts have provided revenue estimates for CRBU’s current fiscal year. The highest revenue estimate was $21M, while the lowest revenue estimate was $–, resulting in an average revenue estimate of $12.27M. In the same quarter a year ago, actual revenue was $34.48M, down -64.40% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $12.97M in the next fiscal year. The high estimate is $24M and the low estimate is $–. The average revenue growth estimate for next year is up 5.70% from the average revenue estimate for this year.
